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A number of studies and analyses 
have illustrated the increased rate of 
cardiovascular disease conferred by 
multiple risk factors.1,2  Up to now, 
however, the primary focus for 
addressing cardiovascular risk has been 
the treatment of each risk factor 
separately (e.g., LDL cholesterol, 
hypertension, and diabetes).  Major gaps 
in our overall understanding of the ways 
in which these individual risk factors act 
together in creating an increased 
cardiovascular risk exist.  Still, an 
emerging focus on the additive nature of 
multiple risks has led to an effort to 
reduce the overall number of risk factors 
and evaluate the relative strength of the 
effect of each on the others.  The 
development of the metabolic syndrome 
(defined as the presence of three or more 
of five individual risk factors including 
elevated triglycerides, low levels of 
HDL-C, elevated blood pressure, 
expanded waist circumference, and 
borderline elevated glucose or diabetes) 
represents a notable example of a more 
global risk factor assessment (Figure 1).3  
 
The Role of Visceral Adiposity 
In searching for a place to start, 
obesity, perhaps more than any other 
single risk, plays the central role in 
overall cardiometabolic risk.  In fact, 
obesity appears to be a major driver of 
insulin resistance, which in turn, can 
result in dyslipidemia, hypertension, 
inflammation, and even glucose 
intolerance and diabetes.4   A case can be 
made that obesity is the risk factor that 
drives the entire metabolic syndrome. 
Figure 1. Cardiovascular mortality 
increases with number of risk factors. 
CVD mortality increases with number 
of risk factors.
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It is important to recognize that not 
all fat is created equal.  The International 
Diabetes Foundation (IDF) identified 
visceral obesity as the most critical 
cardiovascular risk.5  Abdominal obesity 
appears to be a greater predictor of non-
insulin-dependent diabetes mellitus 
(NIDDM) than overall obesity (Figure 
2).6  Indeed, visceral adiposity (not 
overall obesity) appears to be the 
primary predictor of both NIDDM and 
the metabolic syndrome in general.7-9  
 
The Endocannabinoid System 
In the midst of research on 
cardiovascular risks and visceral 
adiposity, a previously little known 
physiologic system has been identified 
that appears to play a major role in the 
co-regulation of interactions between fat 
and other physiologic systems.  First 
suggested  during  the  recognition of the 
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Figure 2.  Age-adjusted relative risk of Type 2 diabetes by baseline waist circumference 
(WC), waist-to-hip ratio (WHR), and BMI deciles. 
 
 
appetite-inducing properties of the 
cannabinoid, Cannabis Sativa,10 the 
endocannabinoid system (ECS) was not 
well understood until the discovery of 
endogenous cannabinoids (ECs) and 
their receptors.  Despite this late start, 
the last twenty years has seen a 
remarkable increase in researchers’ 
understanding of the structure and vital 
function of the ECS.   
The initial discovery of where 
cannabinoids bind to sites in the brain of 
rats was followed by the discovery of 
two endogenously-produced cannabi-
noids, anandamide and 2-arachinodonyl 
glycerol.  The binding sites for these 
cannabinoids include the CB1 receptor, 
which is involved in the regulation of 
energy homeostasis, and the CB2 
receptor, which is found primarily in the  
immune system and is not thought to 
play a significant role in feeding or 
energy balancing.11 
Once these basic elements of the 
ECS were described, research turned to 
how the system functions.  The CB1 
receptors are activated by endocanna-
binoids, which are arachidonic-acid 
derivatives    that    are    synthesized   as 
needed,  then  bind to the CB1 receptors.   
 
Upon binding, they activate the system, 
then rapidly degrade.  Endocannabinoid 
production and binding with CB1 
receptors modulates energy balance and 
metabolism in the brain and also is 
active in adipose tissue, the liver, 
skeletal muscle, and the gut.12 
Centrally, CB1 activation stimulates 
food intake directly by increasing the 
motivation to eat and the sensory appeal 
of food.13  In addition, CB1 receptors in 
the hypothalamus appear to participate 
in hunger and satiety signaling.13  The 
direct evidence of this central activation 
of the system came with the injection of 
the endocannabinoid anandamide 
directly into the brain of pre-fed and 
satiated rats.  When the ventromedial 
hypothalamus was stimulated in this 
fashion, the rats significantly overate.14  
Having demonstrated that central 
nervous system (CNS) stimulation can 
bolster food intake, genetically 
engineered CB1 receptor-deficient mice 
were underfed, and unlike their normal 
wild-type littermates, the receptor-
deficient mice ate far less when exposed 
to food.15  When rimonabant, a CB1 
antagonist, was added to the daily 
regimen of obese, overfed mice, body 
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weight was reduced.  This confirmed 
that the endocannabinoid system, when 
stimulated, plays a critical role in the 
development of obesity.15 
In addition to the effects on the CNS, 
the actions of the endocannabinoid 
system have been found in peripheral 
tissues, where ECS stimulation is 
believed to modulate a number of other 
mechanisms.  In the liver, CB1 
stimulation appears to facilitate the 
formation and storage of triglycerides 
and to promote lipogenesis and the 
formation of fatty liver.16  In the GI tract, 
cannabinoid and ghrelin levels increase 
together in response to fasting.  When 
the endocannabinoid antagonist 
rimonabant is intraperitoneally injected, 
it has the effect of decreasing 
endocannabinoid and ghrelin levels, 
thereby reducing hunger signals.16  In 
addition to these effects, blockade of 
CB1 receptors appears to upregulate the 
critically important plasma protein 
adiponectin positively, which in turn 
decreases hyperinsulinemia and 
weight.17 
 
ECS in Humans 
Not surprisingly, considering 
these animal studies, human data 
indicate that higher levels of 
endocannabinoids are found in obese 
humans when compared to their lean 
counterparts.  In fact, compared to lean 
subjects, both anandamide and 2-AG 
have been found in significantly higher 
quantities in obese women.18  Further 
studies need to be conducted to ensure 
these findings apply to men.  It is 
interesting, and perhaps not unexpected 
given the difficulty of maintaining 
weight loss, that endocannabinoid levels 
have not been found to decrease during 
weight loss. 
Further evidence of the action of the 
ECS in promoting human obesity comes 
from the discovery of a genetic 
deficiency caused by a missense 
mutation in fatty acid amide hydrolase 
(FAAH; an enzyme that helps degrade 
endocannabinoids).  With a deficiency in 
FAAH, higher circulating levels of the 
endocannabinoids and a significant 
increase in the likelihood of obesity are 
noted (Figure 3).19   In addition, a study 
comparing levels of endocannabinoids in 
human subcutaneous and visceral fatty 
tissues revealed the presence of higher 
levels of endocannabinoids in visceral 
fatty tissue, reinforcing the importance 
of the ECS in preferentially modulating 
the most important human depot of fatty 
tissue: visceral fat.20  
 
Figure 3.  Percentage of subjects with increasing percentage presence of FAAH missense 
by Body Mass Index. 
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The ECS in the Development of 
Cardiometabolic Risk 
Emerging evidence suggests that 
stimulation of the ECS centrally and 
peripherally leads to increased food 
intake, increased waist circumference 
(indicative of increased visceral 
adiposity), elevated triglycerides, 
decreased HDL-cholesterol, and insulin 
resistance.  Recent phase 3 trials on the 
ECS antagonist rimonabant have 
demonstrated its ability to block the 
central and peripheral effects of the 
ECS.  In four phase 3 clinical trials, 
rimonabant was not only associated with 
significant weight loss, but also with a 
decreased waist circumference and 
improved glucose tolerance.21-24  
Interestingly, the improvement in HbA1c 
in the Rimonabant-in-Obesity (RIO) 
Diabetes trial was much greater than 
would have been predicted by the degree 
of weight loss achieved.21 
With additional benefits noted in 
triglyceride levels, HDL-C and blood 
pressure21-24, rimonabant achieved a 
significant decline in a number of 
individual risk factors and in the 
prevalence of the overall metabolic 
syndrome (Figure 4).23  However, a 
major obstacle to approval of rimbonant 
in the United States is the Food and 
Drug Administration Advisory Com-
mittee’s recommendation that approval 
be delayed, pending resolution of safety 
issues concerning increased levels of 
depression and suicide ideation.25 
 
Summary 
In the search for better ways to 
prevent and treat cardiovascular disease, 
notation of multiple risk factors and the 
central role that visceral adiposity plays 
in modulating overall risk are important.  
The challenge of reducing this risk has 
led   to   a   search   for   ways  to  reduce 
Figure 4.  Change from baseline in 
metabolic syndrome status at one year. 
 
 
adiposity consistently and efficiently 
while positively impacting other classic 
cardiovascular risks.  The discovery of 
the ECS and the ability to block the 
effects of its over-stimulation gives a 
new approach to reduce multiple 
cardiometabolic risk factors signi-
ficantly.  With continued efforts to 
improve the lifestyles of our patients, 
combined with exciting new pathways 
for pharmacologic intervention, we can 
achieve the reduction in cardiovascular 
risks needed to tame the epidemic of 
obesity-mediated cardiovascular disease.  
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